Chairman’s Introduction: Epidemiology, Late-Breaking Advances, and Evolving Decisions on the Cardiovascular Landscape of Stroke Prevention in Atrial Fibrillation (SPAF) Samuel Z. Goldhaber, MD – Program Chairman
Risk Stratification of Patients with Atrial Fibrillation: Implementation of Risk-Directed Therapy Based on AF Risk Scoring Systems Jonathan L. Halperin, MD
From Risk to Remedy: Deciphering the Maze of Evidence from Landmark Trials Evaluating Non-Monitored, Oral Anticoagulants for SPAF Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Clinical Dilemmas and Decision-Making in Patients Requiring SPAF: Aligning Appropriate Therapies in Low, Moderate, and High Risk Groups with AF—Strategies and Suggestions Samuel Z. Goldhaber, MD – Program Chairman
So What Now? Applying Remedies to for SPAF: Case Studies in SPAF Faculty Panel
